---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-134777"
form_type: "8-K"
ticker: "XOMA"
cik: "0000791908"
company_name: "XOMA Royalty Corp"
filed_at: "2024-05-09T23:59:59+00:00"
generated_at: "2026-06-02T07:40:07.058664+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# XOMA Q1 net loss $8.6M; FDA approves OJEMDA triggering $9M milestone

## Summary
- Q1 revenue $1.5M (vs $0.4M YoY) on $1M AVEO milestone; net loss $8.6M (vs $9.8M YoY).
- FDA approved Day One's OJEMDA; XOMA earned $9M milestone and will receive mid-single digit royalties.
- Acquired Kinnate Pharmaceuticals for $2.5879/share + CVR; adds at least $9.5M non-dilutive capital.
- Expanded royalty portfolio: economic interests in DSUVIA, XACIATO, Ovaprene (Ph3), and Sildenafil Cream.
- Launched first $50M stock buyback; cash $142.4M at March 31, 2024.

## SEC filing metadata
- accession: 0001193125-24-134777
- form_type: 8-K
- ticker: XOMA
- cik: 0000791908
- company_name: XOMA Royalty Corp
- filed_at: 2024-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/791908/000119312524134777/0001193125-24-134777-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/791908/000119312524134777/d841331d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-134777
- JSON: https://secwatch.observer/filing/0001193125-24-134777.json
- Plain text: https://secwatch.observer/filing/0001193125-24-134777.txt

## Key facts
- Earnings Releases
  XOMA Royalty Corp reported the quarter ended March 31, 2024 results: revenue $1.5 million, net income $8.6 million.
  - Period: the quarter ended March 31, 2024
  - Revenue: $1.5 million
  - Net income: $8.6 million
  - Result: reported results
  source text: XOMA recorded total revenues of $1.5 million for the first quarter of 2024, which included a $1.0 million milestone payment received from AVEO Oncology, as compared with $0.4 million in the first quarter of 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/791908/000119312524134777/0001193125-24-134777-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.